Search Results

Exscientia as EVP, Corporate Development Confo Therapeutics Nominated for 'Deal of the Year (>€500 Million

Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development DKK 25 million

Receptor Agonist GSBR-1290 and Provides Program Update Septerna sells GPCR program to Vertex for $48 million

Pfizer’s Vydura recommended by NICE for acute migraines Addex mGlu2 NAM Cognition Program Receives €4 Million

Graeme Milligan and their colleagues research on Pro-phagocytic function and structural basis of GPR84 Biosciences' GPCR Assay Septerna: making another run on GPCRs Addex Mglu2 Nam Cognition Program Receives €4 Million

nanobody binding to its extracellular domain Industry News Superluminal Medicines Launches with $33 Million

Oskar Industry News Addex GABAb Positive Allosteric Modulator Program To Receive Additional Chf 2.7 Million Half-Year 2023 Financial Results And Host Conference Call On August 10, 2023 X4 Pharmaceuticals Closes $115 Million Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023 Septerna: $150 Million

Industry News Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted

Industry News X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market Andrew

However, DL algorithms typically require large amounts of labelled training data comprising millions Unsupervised deep learning that takes advantage of large unlabelled data (e.g., millions of compounds

Bryan Roth, Sudarshan Rajagopal, and Graeme Milligan. Save the date! Dr.

Neurotransmitter release: The last millisecond in the life of a synaptic vesicle.

Structural and Molecular Insights into GPCR Function Sub-millisecond conformational dynamics of the A2A

Publication of its Inaugural ESG Report, for the Financial Year ended 31 December 2022 Addex Raises $5.0 Million

for Type II diabetes approved for first-line treatment The Lundbeck Foundation is awarding DKK 174 million

Biosciences won Out-Licensing Deal of the Year from Locust Walk Omass Therapeutics 2022 Review Sosei hooks millions

Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology experts More millions

Chemical libraries containing fragment- (1.6 million molecules) and lead-like (4.6 million molecules)

Chemical libraries containing fragment- (1.6 million molecules) and lead-like (4.6 million molecules)

This study demonstrates the feasibility of producing milligram quantities of hTAS1R2-VFT to further characterize

molecule candidates across oncology and immunology Exscientia will receive an upfront cash payment of $100 million

License Agreement Neurocrine Biosciences has agreed to pay Sosei Heptares an upfront payment of US$100 million

decades—but the two-year-old biotech believes the area is still ripe for development, and it now has $100 million

Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed $33 million financing round, extending its $100 million Series B financing, which was announced in October 2021.

Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent £388 million on

The move comes less than three weeks after X4 pulled together a $55 million PIPE and amended a loan facility

2016, Abbie Celniker was promoted to partner at Third Rock Ventures as the firm raised just over $600 million

underwriting discounts and commissions and other offering expenses, are expected to be approximately $125.0 million